Resistant hypertension: Baroreflex stimulation as a new tool

Nephrology Dialysis Transplantation

Volumn 28, Issue 2, 2013, Pages 288-295

  Menne, Jan ^a   Jordan, Jens ^a   Linnenweber Held, Silvia ^a   Haller, Hermann ^a  

^a HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

autonomic nerve system; baroreflex activation; renal denervation; resistant hypertension; therapy

Indexed keywords

ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; VASODILATOR AGENT;

ARTICLE; AUTOREGULATION; BLOOD PRESSURE REGULATION; CAROTID SINUS PRESSORECEPTOR; CONTROLLED CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; ELECTROCARDIOGRAPHY; ELECTROSTIMULATION THERAPY; HEART FUNCTION; HEART RATE VARIABILITY; HEMATOMA; HUMAN; IMPLANTABLE NEUROSTIMULATOR; INFECTIOUS COMPLICATION; KIDNEY DENERVATION; LONG TERM CARE; MEDICAL SPECIALIST; NONHUMAN; OUTCOME ASSESSMENT; PAIN; PATIENT SAFETY; POSTOPERATIVE COMPLICATION; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; PUBLIC HEALTH; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESISTANT HYPERTENSION; SURGEON; SYMPATHETIC TONE; THERAPY EFFECT; TREATMENT DURATION; TREATMENT RESPONSE; VAGUS REFLEX; VASCULAR SURGERY;

ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BLOOD PRESSURE; CAROTID ARTERIES; DRUG RESISTANCE; ELECTRIC STIMULATION THERAPY; HUMANS; HYPERTENSION; PRESSORECEPTORS; SYMPATHETIC NERVOUS SYSTEM; TREATMENT OUTCOME;

EID: 84874535754     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfs504     Document Type: Article

References (33)

1. Fagard RH. Resistant hypertension. Heart 2012; 98: 254-261
2. Cuspidi C, Macca G, Sampieri L et al. High prevalence of cardiac and extracardiac target organ damage in refractory hypertension. J Hypertension 2001; 19: 2063-2070 (Pubitemid 33035812)
3. Narkiewicz K, van de Borne PJ, Cooley RL et al. Sympathetic activity in obese subjects with and without obstructive sleep apnea. Circulation 1998; 98: 772-776 (Pubitemid 28391842)
4. Grassi G, Cattaneo BM, Seravalle G et al. Baroreflex control of sympathetic nerve activity in essential and secondary hypertension. Hypertension 1998; 31: 68-72 (Pubitemid 28124694)
5. Hogarth AJ, Mackintosh AF, Mary DA. The sympathetic drive after acute myocardial infarction in hypertensive patients. Am J Hypertens 2006; 19: 1070-1076 (Pubitemid 44485970)
6. Grassi G, Trevano FQ, Seravalle G et al. Baroreflex function in hypertension: consequences for antihypertensive therapy. Prog Cardiovasc Dis 2006; 48: 407-415 (Pubitemid 44250757)
7. Lohmeier TE. The sympathetic nervous system and long-term blood pressure regulation. Am J Hypertens 2001; 14(6 Pt 2): 147S-154S (Pubitemid 32506709)
8. Mancia G, Parati G, Zanchetti A. Electrical carotid baroreceptor stimulation in resistant hypertension. Hypertension 2010; 55: 607-609
9. Scheffers IJ, Kroon AA, de Leeuw PW. Carotid baroreflex activation: past, present, and future. Curr Hypertens Rep 2010; 12: 61-66
10. Scheffers IJ, Kroon AA, Tordoir JH et al. Rheos baroreflex hypertension therapy system to treat resistant hypertension. Expert Rev Med Devices 2008; 5: 33-39
11. Lohmeier TE, Barrett AM, Irwin ED. Prolonged activation of the baroreflex: a viable approach for the treatment of hypertension? Curr Hypertens Rep 2005; 7: 193-198 (Pubitemid 40894925)
12. Heusser K, Tank J, Engeli S et al. Carotid baroreceptor stimulation, sympathetic activity, baroreflex function, and blood pressure in hypertensive patients. Hypertension 2010; 55: 619-626
13. Wustmann K, Kucera JP, Scheffers I et al. Effects of chronic baroreceptor stimulation on the autonomic cardiovascular regulation in patients with drug-resistant arterial hypertension. Hypertension 2009; 54: 530-536
14. Scheffers IJ, Kroon AA, Schmidli J et al. Novel baroreflex activation therapy in resistant hypertension: results of a European multi-center feasibility study. J Am Coll Cardiol 2010; 56: 1254-1258
15. Bisognano JD, Bakris G, Nadim MK et al. Baroreflex activation therapy lowers blood pressure in patients with resistant hypertension: results from the double-blind, randomized, placebo-controlled rheos pivotal trial. J Am Coll Cardiol 2011; 58: 765-773
16. Hoppe UC, Brandt MC, Wachter R et al. Minimally invasive system for baroreflex activation therapy chronically lowers blood pressure with pacemaker-like safety profile: results from the Barostim neo trial. J Am Soc Hypertens 2012; 6: 270-276
17. Bakris GL, Nadim MK, Haller H et al. Baroreflex activation therapy provides durable benefit in patients with resistant hypertension: results of long-term follow-up in the Rheos Pivotal Trial. J Am Soc Hypertens 2012; 6: 152-158
18. Bisognano JD, Kaufman CL, Bach DS et al. Improved cardiac structure and function with chronic treatment using an implantable device in resistant hypertension: results from European and United States trials of the Rheos system. J Am Coll Cardiol 2011; 57: 1787-1788
19. Krum H, Schlaich M, Sobotka P et al. Novel procedure-and devicebased strategies in the management of systemic hypertension. Eur Heart J 2011; 32: 537-544
20. Schmieder RE, Redon J, Grassi G et al. ESH position paper: renal denervation-an interventional therapy of resistant hypertension. J Hypertens 2012; 30: 837-841
21. Persu A, Renkin J, Thijs L et al. Renal denervation: ultima ratio or standard in treatment-resistant hypertension. Hypertension 2012; 60: 596-606
22. Lohmeier TE, Hildebrandt DA, Dwyer TM et al. Renal denervation does not abolish sustained baroreflex-mediated reductions in arterial pressure. Hypertension 2007; 49: 373-379 (Pubitemid 46143015)
23. Lohmeier TE, Iliescu R, Liu B et al. Systemic and renal-specific sympathoinhibition in obesity hypertension. Hypertension 2012; 59: 331-338
24. Brinkmann J, Heusser K, Schmidt BM et al. Catheter-based renal nerve ablation and centrally generated sympathetic activity in difficult hypertensive patients: Case series. Hypertension 2012; [Epub ahead of print October 8]
25. Schlaich MP, Sobotka PA, Krum H et al. Renal sympathetic-nerve ablation for uncontrolled hypertension. N Engl J Med 2009; 361: 932-934
26. Sleight P. Nonpharmacological treatments for hypertension. J Hypertens 2012; 30: 1516-1517
27. Alnima T, Scheffers I, De Leeuw PWet al. Sustained acute voltagedependent blood pressure decrease with prolonged carotid baroreflex activation in therapy-resistant hypertension. J Hypertens 2012; 30: 1665-1670
28. Iliescu R, Irwin ED, Georgakopoulos D et al. Renal responses to chronic suppression of central sympathetic outflow. Hypertension 2012; 60: 749-756
29. Parati G, Bilo G. Arterial baroreflex modulation of sympathetic activity and arterial wall properties: new evidence. Hypertension 2012; 59: 5-7
30. Grassi G, Bertoli S, Seravalle G. Sympathetic nervous system: role in hypertension and in chronic kidney disease. Curr Opin Nephrol Hypertens 2012; 21: 46-51
31. Lohmeier TE, Iliescu R. Chronic lowering of blood pressure by carotid baroreflex activation: mechanisms and potential for hypertension therapy. Hypertension 2011; 57: 880-886
32. Esler MD, Krum H, Sobotka PA et al. Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): a randomised controlled trial. Lancet 2010; 376: 1903-1909
33. Krum H, Schlaich M, Whitbourn R et al. Catheter-based renal sympathetic denervation for resistant hypertension: a multicentre safety and proof-of-principle cohort study. Lancet 2009; 373: 1275-1281